A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol

Inclusion Criteria:

- Participants must be healthy males or females without childbearing potential as
determined by medical history and physical examination, including first-generation
Japanese participants

- Have body mass indexes of 18 to 35 kilograms per meter square (kg/m^2), inclusive, at
screening

- Have screening low-density lipoprotein cholesterol (LDL-C) of between 100 and 180
milligrams per deciliter (mg/dL), inclusive

Exclusion Criteria:

- Have known allergies to compounds related to LY3015014 or any components of the
formulation or known clinically significant hypersensitivity to biologic agents

- Have a history of atopy, significant allergies to humanized monoclonal antibodies,
clinically significant multiple or severe drug allergies, intolerance to topical
corticosteroids, or severe posttreatment hypersensitivity reactions [including but not
limited to erythema multiforme major, linear immunoglobulin (Ig)A dermatosis, toxic
epidermal necrolysis, or exfoliative dermatitis)

- Have significant history of or current cardiovascular, respiratory, hepatic, renal,
gastrointestinal, endocrine, hematological, or neurological disorders capable of
significantly altering the absorption, metabolism, or elimination of drugs, of
constituting a risk when taking the study medication, or of interfering with the
interpretation of data

- Have received any vaccine(s) within 1 month of LY3015014 dosing or intend to do so
during the study

- Have received treatment with biologic agents (such as monoclonal antibodies) within 3
months or 5 half-lives (whichever is longer) prior to dosing